NRX Pharma Clears FDA Milestone – Ketafree Could Become First Preservative-Free IV Ketamine

Healthcare investors: NRX Pharmaceuticals (NASDAQ: NRXP) has reached a major regulatory milestone with its investigational ketamine therapy.

In this NewsOut segment, Anna Berry reports that the U.S. FDA has officially received and accepted as substantially complete the company’s Abbreviated New Drug Application (ANDA) for KetaFree, a preservative-free intravenous ketamine formulation.

💊 Why This Matters

If approved, KetaFree could become the first preservative-free IV ketamine product available in the United States, addressing safety concerns around preservatives included in standard ketamine vials.

🏭 Manufacturing Readiness

NRX reports it has already manufactured initial registration batches and can scale production to:

Up to 1 million vials per month

This signals readiness to meet anticipated commercial demand.

📅 Regulatory Timeline

FDA review goal date: July 29, 2026

Approval could occur at or before this date if the review process remains on schedule.

📈 Market Implications

The development is important for:

Patients and prescribers seeking safer ketamine treatment options

Investors tracking the expanding depression treatment and suicide prevention markets

#NRXP
#NRXPharma
#Ketafree
#KetamineTherapy
#FDAApproval
#PharmaceuticalStocks
#MentalHealthTech
#DepressionTreatment
#HealthcareInvesting
#BiotechNews
#NASDAQ
#AnnaBerry
#NewsOut
#IVKetamine
#DrugDevelopment